it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done. .
stephen silberstein, md, director, jefferson university headache center. .
884 Used Today
77 Used Today
323 Used Today
the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid. .